consenso-venezolano-en-cc3a1ncer-epitelial-de-ovario-2013

260
Primer Consenso Nacional de cáncer epitelial de ovario
diagnóstica de la biopsia per-operatoria es muy
alta para los tumores del espectro benigno y
maligno, pero la sensibilidad es menor en los
tumores de bajo potencial de malignidad por las
razones ya descritas.
REFERENCIAS
1. Kurman RJ, Ming S. Pathogenesis of ovarian cancer.
Lessons from morphology and molecular biology
and their clinical implications. Int J Gynecol Pathol.
2008;27(2):151-160.
2. Jazaeri A, Bryan J, Park H, Li H, Dahiya N, Stoler M,
et al. A transformation of Fallopian tube epithelial cells
into serous carcinoma. Neoplasia. 2011;13: 899-911.
3. Li J, Abushahin N, Pang Li, Setsuko X , Chambers K,
Beihua F, et al. Tubal origin of ‘ovarian’ low-grade
serous carcinoma. Mod Pathol. 2011;24:1488-1499.
4. Cho KR. Ovarian cancer update. Lessons from
morphology, molecules, and mice. Arch Pathol Lab
Med. 2009;133(11):1775-1781.
5. Scully RE. Classification of human ovarian tumors.
Environ Health Perspec.1987;78:15-18.
6. Scully RE. Ovarian tumors. A Review. Am J Pathol.
1977;(87):687-720.
7. Chen V, Ruiz, B, Killeen J, Cote T, Wu X, Correa
C. Pathology and classification of ovarian tumors.
Cancer. 2003; 97(Suppl 10):2631-2642.
8. Bostwick D, Tazelaar H, Ballon S, Hendrickson
M, Kempson R. A clinical and pathologic study of
109 cases. Ovarian epithelial tumors of borderline
malignancy. Cancer. 1986;58:2052-2065.
9. Hart W. Borderline epithelial tumors of the ovary.
Mod Pathol. 2005;18:S33-50.
10. Kennedy A, Hart W. Ovarian papillary serous tumors
of low malignant potential (serous borderline tumors)
a long term follow-up study, including patients
with micro-invasion, lymph node metastasis, and
transformation to invasive serous carcinoma. Cancer.
1996;(78);278-296.
11. Yemelyanova A, Lien Mao T, Nakayama N, Shih M,
Kurman R. Low-grade serous carcinoma of the ovary
displaying a macro-papillary pattern of invasion. Am
J Surg Pathol. 2008;14(12):1800-1806.
12. Gershenson D. Is micro-papillary serous carcinoma
for real? Cancer. 2002;95(4):677-680.
13. Leitao MMJ. Micro-papillary pattern in newly
diagnosed borderline tumors of the ovary: What’s in
a name? Oncologist. 2011;16(2):133-135.
14. Vang R, Shih L, Kurman RJ. Ovarian low-grade
and high-grade serous carcinoma: Pathogenesis,
clinic pathologic and molecular biologic features,
and diagnostic problems. Adv Anat Pathol.
2009;16(5):267-282.
15. Malpica A. Grading of ovarian cancer: A histo-typespecific
approach. A review. Int J Gynecol Pathol.
2008;27(2):175-181.
16. Prat J. Ovarian carcinomas, including secondary
tumors: Diagnostically challenging areas. Mod Pathol.
2005;18:S99-111.
17. Czernobilsky B, Borenstein R, Lancet M.
Cystadenofibroma of the ovary. A clinic pathologic
study of 34 cases and his comparison with serous
cystadenoma. Cancer. 1974;34(6):1971-81.
18. Hart W, Norris H. Borderline and malignant mucinous
tumors of the ovary. Histologic criteria and clinical
behavior. Cancer. 1973;31:1031-1045.
19. Guerrieri C, Hogberg T, Wingren S, Fristedt S,
Simonsen E, Boeryd B. Mucinous borderline and
malignant tumors of the ovary: A clinic pathologic and
DNA ploidy study of 92 cases. Cancer. 1994;74:2329-
2340.
20. Nomura K, Aizawa S. Non-invasive, micro-invasive,
and invasive mucinous carcinomas of the ovary:
A clinic pathologic analysis of 40 cases. Cancer.
2000;89(7):1541-1546.
21. Cernobilsmkdy B, Silverman B, Mikutam, J.
Endometrioid carcinoma of the ovary a clinic pathologic
study of 75 cases. Cancer. 1970;26(5):1141-1152.
22. Kurman R, Craig JM. Endometrioid and clear cell
carcinoma of the ovary. Cancer. 1972;29(6):1653-
1664.
23. McCluggage WG. My approach to and thoughts
on the typing of ovarian carcinomas. J Clin Pathol.
2008;61:152-163
24. Kao G, Norris H. Benign and low grade variants of
mixed mesodermal tumor (adenosarcoma) of the ovary
and adnexal region. Cancer. 1978;42:1314-1324.
25. Zhao C, Wu SL, Barner R. Pathogenesis of ovarian clear
cell adenofibroma, atypical proliferative (Borderline)
tumor, and carcinoma: Clinic pathologic features
of tumors with endometriosis or adenofibromatous
components support two related pathways of tumor
development. J Cancer. 2011;2:94-106.
Vol. 26, Nº 3, septiembre 2014